Why the study?
Does the combination of leupeptin and indomethacin synergistically prevent activation of human platelets?
Does the combination of leupeptin and indomethacin synergistically prevent activation of human platelets?
The combination of protease and cyclooxygenase inhibitors synergistically prevents human platelet activation, suggesting a potential strategy to enhance antiplatelet therapy while lowering cyclooxygenase inhibitor doses.
May support dual protease-COX inhibition in preclinical platelet models; leaves open human translation and clinical testing.
Thrombin induces platelet aggregation and formation of a fibrin clot in platelet-rich plasma; leupeptin, a protease inhibitor, partially inhibits platelet aggregation, but it does not inhibit fibrin clot formation. Indomethacin does not inhibit either thrombin-induced platelet aggregation or fibrin clot formation. However, when the two drugs are given together, a synergistic inhibition of thrombin-induced platelet aggregation occurs, while fibrin clot formation remains unaffected. Thrombin-induced stimulation of the release of serotonin in washed human platelets is also synergistically inhibited by the combined actions of leupeptin and indomethacin. Thrombin and collagen, added simultaneously, induce full platelet aggregation and release of serotonin. Neither leupeptin nor indomethacin inhibits platelet responses elicited by both agonists; however, when leupeptin and indomethacin are given together, a synergistic inhibition of thrombin- and collagen-induced response is observed. These findings might be relevant in prophylaxis and treatment of thromboembolic disease.
No takes yet. Share an insight, caveat, or question.
Ruggiero et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: